News | Radiopharmaceuticals and Tracers | April 13, 2017

University of Missouri Research Reactor Files to Start U.S. Production of Medical Isotopes

Facility expected to begin sending molybdenum-99 to partners in mid- to late 2018

University of Missouri Research Reactor Files to Start U.S. Production of Medical Isotopes

April 13, 2017 — The University of Missouri Research Reactor (MURR) and its partners Nordion and General Atomics (GA), announced in March that MURR’s License Amendment Request (LAR) has been submitted to the U.S. Nuclear Regulatory Commission (NRC). This marks a critical step towards implementing domestic U.S. production of molybdenum-99 (Mo-99). Once operational, production from this facility will be capable of supporting nearly half of U.S. demand for Mo-99, which currently must be imported from outside North America.

A medical isotope is a safe radioactive substance used by health professionals to diagnose and treat patients who suffer from a variety of conditions, including cardiovascular disease and cancer. Almost 50 million such procedures are performed every year. The most important isotope, technetium-99m (Tc-99m), is produced from Mo-99 and is used in more than 80 percent of all nuclear medicine procedures.

“This LAR submission shows the Nuclear Regulatory Commission that we will have all of the technology, expertise and safety measures needed to begin producing Mo-99 in place and ready to go once approval has been received,” said Ralph Butler, executive director of MURR. “As a public research institution, we are proud to play a partnership role with GA and Nordion in helping America secure a new, domestic source of Mo-99.”

Once approved by the NRC, MURR will begin producing Mo-99 using selective gaseous extraction (SGE), a proprietary technology developed by General Atomics to extract the isotope from Low Enriched Uranium (LEU) targets. This patented approach will produce Mo-99 of the highest specific activity, while avoiding the production of liquid uranium waste, a significant problem with existing technologies that require Highly Enriched Uranium (HEU). Extracted Mo-99 will be transported to Nordion’s facility in Ottawa, Ontario, for final purification and distribution to radiopharmaceutical manufacturers, after which it will be distributed to hospitals and medical facilities around the world.

Nordion will start receiving Mo-99 from MURR in mid- to late 2018, according to Phil Larabie, vice president, medical isotopes for Nordion. In addition, Nordion is maintaining its conventional Mo-99 processing capacity through March 31, 2018, in the event of a significant global shortage of Mo-99.

The MURR project is being conducted with the active support of the U.S. Department of Energy’s National Nuclear Security Administration (NNSA), which was mandated to help secure a new, reliable domestic supply of Mo-99 by the American Medical Isotopes Production Act of 2012 (AMIPA). The approval of MURR’s LAR represents a major step toward achieving this goal.

For more information: www.murr.missouri.edu

Related Content

GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages
PET Imaging Offers New Possibilities in Chronic Liver Disease Management

Hepatic 18F-FDG, 18F-FAC, and 18F-DFA accumulation are affected in a mouse model of autoimmune hepatitis. (A) Histochemical and immunohistochemical analyses of liver sections from vehicle- and ConA-treated mice. Scale bars represent 50 microns. Transverse PET/CT images (B) and quantification (C) of vehicle- and ConA-treated mice injected with 18F-FDG, 18F-FAC, and 18FDFA. Livers are outlined in a white dotted line. Quantification represents radiotracer accumulation in the liver normalized to a background organ. Image courtesy of Salas J.R., Chen B.Y., Wong A., et al.

News | PET Imaging | October 24, 2018
While liver biopsies are powerful and reliable, they are also invasive, painful, limited and subject to complications....
CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc.
Huntsman Cancer Institute Installs First Preclinical nanoScan 3T PET/MRI in U.S.
News | PET-MRI | October 10, 2018
The Center for Quantitative Cancer Imaging at Huntsman Cancer Institute (HCI) at the University of Utah in Salt Lake...